- Conditions
- Chronic Kidney Disease
- Interventions
- Finerenone (BAY94-8862), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 176
- States / cities
- Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 125 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 2,222
matching trials from the live ClinicalTrials.gov search.
- Conditions
- No History of ADHD, Attention Deficit Hyperactivity Disorder (ADHD), Healthy Volunteer
- Interventions
- QbMobile
- Device
- Lead sponsor
- Qbtech AB
- Industry
- Eligibility
- 6 Years to 60 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- San Jose, California • Largo, Florida • Orlando, Florida
- Conditions
- Asthma
- Interventions
- Vitamin D3, Ciclesonide
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 16
- States / cities
- San Francisco, California • Denver, Colorado • Atlanta, Georgia + 10 more
- Conditions
- Tourette Syndrome, Chronic Tic Disorder, Oppositional Defiant Disorder, ADHD
- Interventions
- Anger control training
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 11 Years to 16 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Shock
- Interventions
- USCOM
- Device
- Lead sponsor
- Hennepin Healthcare Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Implantable Cardioverter Defibrillators, CRT-D Cardiac Resynchronization Therapy Defibrillator
- Interventions
- Not listed
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 44 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Dapagliflozin, Insulin, Liraglutide, Dapagliflozin placebo
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- ADHD
- Interventions
- EndeavorRx
- Device
- Lead sponsor
- Akili Interactive Labs, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 150 participants
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Daratumumab, Echocardiography, Fludarabine, Hematopoietic Cell Transplantation, Indium In 111-DOTA-Daratumumab, Melphalan, Multigated Acquisition Scan, Radionuclide Imaging, Single Photon Emission Computed Tomography, Sirolimus, Tacrolimus, Total Marrow and Lymphoid Irradiation
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- semaglutide, Dulaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 100
- States / cities
- Tuscumbia, Alabama • Chandler, Arizona • Phoenix, Arizona + 85 more
- Conditions
- Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Interventions
- BCG Solution, Biopsy of Bladder, Cystoscopy, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Transurethral Resection of Bladder Tumor, Gemcitabine
- Biological · Procedure · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 52 more
- Conditions
- Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, Working Memory
- Interventions
- Transcranial Magnetic Stimulation (TMS), High controllability TMS target
- Device · Procedure
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 28 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Active transcranial photobiomodulation, Sham transcranial photobiomodulation
- Device
- Lead sponsor
- Francisco Gonzalez-Lima, PhD
- Other
- Eligibility
- 18 Years to 44 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Adjunctive Treatment of Major Depressive Disorder
- Interventions
- CLE-100, placebo
- Drug
- Lead sponsor
- Clexio Biosciences Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 45
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 39 more
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- ABT-089
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 12
- States / cities
- Lafayette, California • Jacksonville, Florida • Orlando, Florida + 9 more
- Conditions
- Skin Angiosarcoma, Skin Radiation-Related Angiosarcoma, Visceral Angiosarcoma
- Interventions
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Nivolumab, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 170
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 120 more
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Danicopan, Placebo, C5 Inhibitor
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Weston, Florida • Chicago, Illinois + 4 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- atomoxetine, Behavior Modification Therapy
- Drug · Behavioral
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- ADHD
- Interventions
- EndeavorOTC
- Device
- Lead sponsor
- Akili Interactive Labs, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 198 participants
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Sclerosis
- Interventions
- Teriflunomide, Placebo (for teriflunomide), Interferon-β [IFN-β], Glatiramer Acetate [GA]
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Cytarabine, Echocardiography Test, Etoposide Phosphate, Mitoxantrone Hydrochloride, Multigated Acquisition Scan, Peposertib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 15
- States / cities
- Duarte, California • Los Angeles, California • Newport Beach, California + 11 more
- Conditions
- Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Etoposide, Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Radiation · Drug · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 532
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 400 more
- Conditions
- ADHD, Autism
- Interventions
- Very Low Dose Quillivant XR, Low Dose Quillivant XR, Moderate Dose Quillivant XR
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 5 Years to 16 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- ADA-SCID
- Interventions
- Infusion of autologous EFS-ADA LV CD34+ (OTL-101), busulfan, PEG-ADA ERT
- Genetic · Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Bethesda, Maryland